Founded 2016Subsidiary of Lin Bioscience International Ltd
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company provides the research and development of novel therapeutics with unmet medical needs in the United States.
Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
It also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease Including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Founded in 2016, Belite Bio is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Belite Bio, Inc is a clinical stage biopharmaceutical company focused on developing novel therapeutics for unmet medical needs. Its lead product candidate is Tinlarebant (LBS-008), an orally administered drug currently in Phase 3 clinical trials for Stargardt disease type 1 and geographic atrophy, both of which are retinal degenerative conditions. The company is also developing LBS-009, a retinol binding protein 4 oral therapy in preclinical stages, targeting liver diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and type 2 diabetes, as well as gout. Belite Bio operates in the biotechnology industry within the healthcare sector.
Where is Belite Bio (BLTE) listed and what currency does it trade in?
Belite Bio, Inc is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol BLTE. Its shares are traded in US Dollars (USD), reflecting its primary listing in the United States. The company is headquartered in San Diego, California, and its stock is accessible to investors through US-based brokerage platforms.
What sector and industry does Belite Bio (BLTE) belong to?
Belite Bio operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical stage biopharmaceutical company, it focuses on research and development of novel therapeutics for diseases with limited treatment options. The biotechnology industry involves using biological processes and organisms to develop drugs and therapies, and Belite Bio's pipeline includes treatments for retinal diseases and liver conditions.
Where is Belite Bio (BLTE) headquartered and what markets does it serve?
Belite Bio, Inc is based in San Diego, California, United States. The company primarily serves the US market, as indicated by its operations being described as providing research and development of novel therapeutics in the United States. It operates as a subsidiary of Lin Bioscience International Ltd. While its clinical trials and development activities are US-focused, the diseases it targets, such as Stargardt disease and non-alcoholic steatohepatitis, have global patient populations.
What is Belite Bio's (BLTE) business model and key pipeline assets?
Belite Bio is a clinical stage biopharmaceutical company that generates value through the research and development of novel therapeutics. Its business model relies on advancing drug candidates through clinical trials to address unmet medical needs. The lead asset, Tinlarebant (LBS-008), is an oral therapy in Phase 3 trials for retinal diseases like Stargardt disease type 1 and geographic atrophy. Another candidate, LBS-009, is in preclinical development for liver diseases including NAFLD, NASH, type 2 diabetes, and gout. The company does not yet have approved products or reported revenue from product sales, as it is still in the development stage.